BIOMAT Database Logo BIOMAT Database Logo

The optimal dose of oral norethindrone acetate for addition to transdermal estradiol: a multicenter study. 1990

D I Fraser, and A Parsons, and M I Whitehead, and J Wordsworth, and G Stuart, and J Pryse-Davies
King's College School of Medicine and Dentistry Hospital, Academic Department of Obstetrics and Gynaecology, London, United Kingdom.

The effects of adding one of three doses (0.5, 0.75, or 1.0 mg/d) of norethindrone acetate for 12 days each month to continuous, transdermal estradiol (0.05 mg/d) have been determined in a prospective, randomized, multicenter study. Significant symptomatic and psychological improvements were observed and, with one exception, were not opposed by the added progestogen. Distinct redness at the site of last patch application was reported by 10% of patients and faint erythema by 30%. However, less than 5% of patients discontinued treatment because of skin problems. Breakthrough bleeding occurred infrequently and all three doses of norethindrone acetate induced a regular pattern of bleeding with secretory transformation in the endometrium. There was no hyperplasia or carcinoma.

UI MeSH Term Description Entries
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009640 Norethindrone A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION. 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17alpha)-,Ethinylnortestosterone,Norethisterone,Norpregneninolone,Conceplan,Micronor,Monogest,Nor-QD,Norcolut,Norcolute,Norethindrone, (1 beta)-Isomer,Norlutin,Nor QD,NorQD
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004717 Endometrium The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo. Endometria
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D006113 United Kingdom Country in northwestern Europe including Great Britain and the northern one-sixth of the island of Ireland, located between the North Sea and north Atlantic Ocean. The capital is London. Great Britain,Isle of Man
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

D I Fraser, and A Parsons, and M I Whitehead, and J Wordsworth, and G Stuart, and J Pryse-Davies
Dose-finding study of a contraceptive ring releasing norethindrone acetate/ethinyl estradiol.
December 1994, Contraception,
D I Fraser, and A Parsons, and M I Whitehead, and J Wordsworth, and G Stuart, and J Pryse-Davies
A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group.
October 1999, Obstetrics and gynecology,
D I Fraser, and A Parsons, and M I Whitehead, and J Wordsworth, and G Stuart, and J Pryse-Davies
A new low dose norethindrone acetate (0.6 mg) ethinyl estradiol (30 mcg) combination oral contraceptive.
March 1974, The Journal of reproductive medicine,
D I Fraser, and A Parsons, and M I Whitehead, and J Wordsworth, and G Stuart, and J Pryse-Davies
Relugolix, Estradiol, and Norethindrone Acetate.
September 2021, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
D I Fraser, and A Parsons, and M I Whitehead, and J Wordsworth, and G Stuart, and J Pryse-Davies
Sequential addition of low dose of medrogestone or medroxyprogesterone acetate to transdermal estradiol: a pilot study on their influence on the endometrium.
September 1996, European journal of obstetrics, gynecology, and reproductive biology,
D I Fraser, and A Parsons, and M I Whitehead, and J Wordsworth, and G Stuart, and J Pryse-Davies
A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms.
January 2005, Gynecologic and obstetric investigation,
D I Fraser, and A Parsons, and M I Whitehead, and J Wordsworth, and G Stuart, and J Pryse-Davies
Effects of oral and transdermal 17beta-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women.
June 2000, Metabolism: clinical and experimental,
D I Fraser, and A Parsons, and M I Whitehead, and J Wordsworth, and G Stuart, and J Pryse-Davies
Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive.
September 2013, Obstetrics and gynecology,
D I Fraser, and A Parsons, and M I Whitehead, and J Wordsworth, and G Stuart, and J Pryse-Davies
Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study.
January 2002, American journal of obstetrics and gynecology,
D I Fraser, and A Parsons, and M I Whitehead, and J Wordsworth, and G Stuart, and J Pryse-Davies
Norethindrone acetate and estradiol-induced endometrial hyperplasia.
September 2000, Obstetrics and gynecology,
Copied contents to your clipboard!